Literature DB >> 24607294

Continuous covariate imbalance and conditional power for clinical trial interim analyses.

Jody D Ciolino1, Renee' H Martin2, Wenle Zhao2, Edward C Jauch2, Michael D Hill3, Yuko Y Palesch2.   

Abstract

Oftentimes valid statistical analyses for clinical trials involve adjustment for known influential covariates, regardless of imbalance observed in these covariates at baseline across treatment groups. Thus, it must be the case that valid interim analyses also properly adjust for these covariates. There are situations, however, in which covariate adjustment is not possible, not planned, or simply carries less merit as it makes inferences less generalizable and less intuitive. In this case, covariate imbalance between treatment groups can have a substantial effect on both interim and final primary outcome analyses. This paper illustrates the effect of influential continuous baseline covariate imbalance on unadjusted conditional power (CP), and thus, on trial decisions based on futility stopping bounds. The robustness of the relationship is illustrated for normal, skewed, and bimodal continuous baseline covariates that are related to a normally distributed primary outcome. Results suggest that unadjusted CP calculations in the presence of influential covariate imbalance require careful interpretation and evaluation.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Conditional power; Covariate adjusted analysis; Covariate imbalance

Mesh:

Year:  2014        PMID: 24607294      PMCID: PMC4024327          DOI: 10.1016/j.cct.2014.02.007

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  22 in total

Review 1.  The role of covariates in estimating treatment effects and risk in long-term clinical trials.

Authors:  Ian Ford; John Norrie
Journal:  Stat Med       Date:  2002-10-15       Impact factor: 2.373

2.  Covariate adjustment in randomized controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements.

Authors:  Adrián V Hernández; Ewout W Steyerberg; J Dik F Habbema
Journal:  J Clin Epidemiol       Date:  2004-05       Impact factor: 6.437

3.  Covariate imbalance and random allocation in clinical trials.

Authors:  S J Senn
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

4.  The B-value: a tool for monitoring data.

Authors:  K K Lan; J Wittes
Journal:  Biometrics       Date:  1988-06       Impact factor: 2.571

5.  Sequential monitoring of clinical trials: the role of information and Brownian motion.

Authors:  K K Lan; D M Zucker
Journal:  Stat Med       Date:  1993-04-30       Impact factor: 2.373

6.  Testing for baseline balance in clinical trials.

Authors:  S Senn
Journal:  Stat Med       Date:  1994-09-15       Impact factor: 2.373

7.  How to select covariates to include in the analysis of a clinical trial.

Authors:  G M Raab; S Day; J Sales
Journal:  Control Clin Trials       Date:  2000-08

8.  Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems.

Authors:  Stuart J Pocock; Susan E Assmann; Laura E Enos; Linda E Kasten
Journal:  Stat Med       Date:  2002-10-15       Impact factor: 2.373

9.  Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome.

Authors:  Roy G Brower; Paul N Lanken; Neil MacIntyre; Michael A Matthay; Alan Morris; Marek Ancukiewicz; David Schoenfeld; B Taylor Thompson
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

10.  Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.

Authors:  Timothy John Ingall; William Michael O'Fallon; Kjell Asplund; Lewis Robert Goldfrank; Vicki S Hertzberg; Thomas Arthur Louis; Teresa J Hengy Christianson
Journal:  Stroke       Date:  2004-09-02       Impact factor: 7.914

View more
  6 in total

1.  A group sequential test for treatment effect based on the Fine-Gray model.

Authors:  Michael J Martens; Brent R Logan
Journal:  Biometrics       Date:  2018-03-13       Impact factor: 2.571

2.  Group sequential tests for treatment effect on survival and cumulative incidence at a fixed time point.

Authors:  Michael J Martens; Brent R Logan
Journal:  Lifetime Data Anal       Date:  2019-11-15       Impact factor: 1.588

3.  Impact of minimal sufficient balance, minimization, and stratified permuted blocks on bias and power in the estimation of treatment effect in sequential clinical trials with a binary endpoint.

Authors:  Steven D Lauzon; Wenle Zhao; Paul J Nietert; Jody D Ciolino; Michael D Hill; Viswanathan Ramakrishnan
Journal:  Stat Methods Med Res       Date:  2021-11-29       Impact factor: 2.494

4.  A model-based conditional power assessment for decision making in randomized controlled trial studies.

Authors:  Baiming Zou; Jianwen Cai; Gary G Koch; Haibo Zhou; Fei Zou
Journal:  Stat Med       Date:  2017-09-04       Impact factor: 2.373

5.  Minimal sufficient balance randomization for sequential randomized controlled trial designs: results from the ESCAPE trial.

Authors:  Tolulope T Sajobi; Gurbakhshash Singh; Mark W Lowerison; Jordan Engbers; Bijoy K Menon; Andrew M Demchuk; Mayank Goyal; Michael D Hill
Journal:  Trials       Date:  2017-11-02       Impact factor: 2.279

6.  Ideal vs. real: a systematic review on handling covariates in randomized controlled trials.

Authors:  Jody D Ciolino; Hannah L Palac; Amy Yang; Mireya Vaca; Hayley M Belli
Journal:  BMC Med Res Methodol       Date:  2019-07-03       Impact factor: 4.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.